Literature DB >> 25113750

Global epidemiology of atrial fibrillation.

Faisal Rahman1, Gene F Kwan2, Emelia J Benjamin3.   

Abstract

Atrial fibrillation (AF) is a major public health burden worldwide, and its prevalence is set to increase owing to widespread population ageing, especially in rapidly developing countries such as Brazil, China, India, and Indonesia. Despite the availability of epidemiological data on the prevalence of AF in North America and Western Europe, corresponding data are limited in Africa, Asia, and South America. Moreover, other observations suggest that the prevalence of AF might be underestimated-not only in low-income and middle-income countries, but also in their high-income counterparts. Future studies are required to provide precise estimations of the global AF burden, identify important risk factors in various regions worldwide, and take into consideration regional and ethnic variations in AF. Furthermore, in response to the increasing prevalence of AF, additional resources will need to be allocated globally for prevention and treatment of AF and its associated complications. In this Review, we discuss the available data on the global prevalence, risk factors, management, financial costs, and clinical burden of AF, and highlight the current worldwide inadequacy of its treatment.

Entities:  

Mesh:

Year:  2014        PMID: 25113750     DOI: 10.1038/nrcardio.2014.118

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN: 1759-5002            Impact factor:   32.419


  245 in total

1.  Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial.

Authors:  David A Fitzmaurice; F D Richard Hobbs; Sue Jowett; Jonathon Mant; Ellen T Murray; Roger Holder; J P Raftery; S Bryan; Michael Davies; Gregory Y H Lip; T F Allan
Journal:  BMJ       Date:  2007-08-02

2.  European ancestry as a risk factor for atrial fibrillation in African Americans.

Authors:  Gregory M Marcus; Alvaro Alonso; Carmen A Peralta; Guillaume Lettre; Eric Vittinghoff; Steven A Lubitz; Ervin R Fox; Yamini S Levitzky; Reena Mehra; Kathleen F Kerr; Rajat Deo; Nona Sotoodehnia; Meggie Akylbekova; Patrick T Ellinor; Dina N Paltoo; Elsayed Z Soliman; Emelia J Benjamin; Susan R Heckbert
Journal:  Circulation       Date:  2010-11-16       Impact factor: 29.690

3.  Assessment of stroke risk in Middle Eastern patients with atrial fibrillation: the Gulf SAFE registry.

Authors:  S Apostolakis; M Zubaid; W A Rashed; A A Alsheikh-Ali; W Almahmeed; A Shehab; K Sulaiman; A Alqudaimi; N Asaad; H Amin; D A Lane; G Y H Lip
Journal:  Int J Cardiol       Date:  2013-03-05       Impact factor: 4.164

4.  Risk factors for early death in acute ischemic stroke and intracerebral hemorrhage: A prospective hospital-based study in Asia. Asian Acute Stroke Advisory Panel.

Authors:  K S Wong
Journal:  Stroke       Date:  1999-11       Impact factor: 7.914

5.  A pharmacogenetic versus a clinical algorithm for warfarin dosing.

Authors:  Stephen E Kimmel; Benjamin French; Scott E Kasner; Julie A Johnson; Jeffrey L Anderson; Brian F Gage; Yves D Rosenberg; Charles S Eby; Rosemary A Madigan; Robert B McBane; Sherif Z Abdel-Rahman; Scott M Stevens; Steven Yale; Emile R Mohler; Margaret C Fang; Vinay Shah; Richard B Horenstein; Nita A Limdi; James A S Muldowney; Jaspal Gujral; Patrice Delafontaine; Robert J Desnick; Thomas L Ortel; Henny H Billett; Robert C Pendleton; Nancy L Geller; Jonathan L Halperin; Samuel Z Goldhaber; Michael D Caldwell; Robert M Califf; Jonas H Ellenberg
Journal:  N Engl J Med       Date:  2013-11-19       Impact factor: 91.245

6.  Improving cardiovascular disease management in Australia: NPS MedicineWise.

Authors:  Svetla V Gadzhanova; Elizabeth E Roughead; Mark J Bartlett
Journal:  Med J Aust       Date:  2013-08-05       Impact factor: 7.738

7.  Prevalence and predictors of paroxysmal atrial fibrillation on Holter monitor in patients with stroke or transient ischemic attack.

Authors:  Osama Alhadramy; Thomas J Jeerakathil; Sumit R Majumdar; Emad Najjar; Jonathan Choy; Maher Saqqur
Journal:  Stroke       Date:  2010-10-14       Impact factor: 7.914

8.  Warfarin pharmacogenetics: development of a dosing algorithm for Omani patients.

Authors:  Anil Pathare; Murtadha Al Khabori; Salam Alkindi; Shoaib Al Zadjali; Rhea Misquith; Hammad Khan; Claudine Lapoumeroulie; Andras Paldi; Rajagopal Krishnamoorthy
Journal:  J Hum Genet       Date:  2012-08-02       Impact factor: 3.172

9.  Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry.

Authors:  Ajay K Kakkar; Iris Mueller; Jean-Pierre Bassand; David A Fitzmaurice; Samuel Z Goldhaber; Shinya Goto; Sylvia Haas; Werner Hacke; Gregory Y H Lip; Lorenzo G Mantovani; Alexander G G Turpie; Martin van Eickels; Frank Misselwitz; Sophie Rushton-Smith; Gloria Kayani; Peter Wilkinson; Freek W A Verheugt
Journal:  PLoS One       Date:  2013-05-21       Impact factor: 3.240

10.  High familial risk of atrial fibrillation/atrial flutter in multiplex families: a nationwide family study in Sweden.

Authors:  Bengt Zöller; Henrik Ohlsson; Jan Sundquist; Kristina Sundquist
Journal:  J Am Heart Assoc       Date:  2012-12-31       Impact factor: 5.501

View more
  179 in total

1.  "To treat or not to treat very elderly naïve patients with atrial fibrillation with vitamin K antagonists".

Authors:  Francesco Dentali; Nicola Mumoli; Monica Gianni; Marco Cei
Journal:  Intern Emerg Med       Date:  2015-09-02       Impact factor: 3.397

2.  Association of Atrial Fibrillation and Cancer.

Authors:  Faisal Rahman; Darae Ko; Emelia J Benjamin
Journal:  JAMA Cardiol       Date:  2016-07-01       Impact factor: 14.676

3.  Dabigatran Levels in Elderly Patients with Atrial Fibrillation: First Post-Marketing Experiences.

Authors:  Tomáš Bolek; Matej Samoš; Ingrid Škorňová; Lucia Stančiaková; Ján Staško; Peter Galajda; Peter Kubisz; Marián Mokáň
Journal:  Drugs Aging       Date:  2018-06       Impact factor: 3.923

4.  Hyperuricemia is associated with an increased prevalence of paroxysmal atrial fibrillation in patients with type 2 diabetes referred for clinically indicated 24-h Holter monitoring.

Authors:  A Mantovani; R Rigolon; A Civettini; B Bolzan; G Morani; S Bonapace; C Dugo; G Zoppini; E Bonora; G Targher
Journal:  J Endocrinol Invest       Date:  2017-07-15       Impact factor: 4.256

5.  Hyperuricemia is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes.

Authors:  A Mantovani; R Rigolon; I Pichiri; M Pernigo; C Bergamini; G Zoppini; E Bonora; G Targher
Journal:  J Endocrinol Invest       Date:  2015-07-16       Impact factor: 4.256

Review 6.  A major role for cardiovascular burden in age-related cognitive decline.

Authors:  Chengxuan Qiu; Laura Fratiglioni
Journal:  Nat Rev Cardiol       Date:  2015-01-13       Impact factor: 32.419

Review 7.  Anticoagulation Management in Patients With Atrial Fibrillation and Cirrhosis.

Authors:  Abhishek Shenoy; David Jarava; Matthew J Stotts; Nicolas M Intagliata
Journal:  Clin Liver Dis (Hoboken)       Date:  2021-05-01

8.  Genetic mutations in African patients with atrial fibrillation: Rationale and design of the Study of Genetics of Atrial Fibrillation in an African Population (SIGNAL).

Authors:  Gerald S Bloomfield; Tecla M Temu; Constantine O Akwanalo; Peng-Sheng Chen; Wilfred Emonyi; Susan R Heckbert; Myra M Koech; Imran Manji; Changyu Shen; Matteo Vatta; Eric J Velazquez; Jennifer Wessel; Sylvester Kimaiyo; Thomas S Inui
Journal:  Am Heart J       Date:  2015-06-14       Impact factor: 4.749

9.  Vernakalant versus ibutilide for immediate conversion of recent-onset atrial fibrillation.

Authors:  I Vogiatzis; E Papavasiliou; I Dapcevitch; S Pittas; E Koulouris
Journal:  Hippokratia       Date:  2017 Apr-Jun       Impact factor: 0.471

Review 10.  New approaches to managing nonvalvular atrial fibrillation: what are the thromboembolic implications?

Authors:  Peter J Kudenchuk
Journal:  J Thromb Thrombolysis       Date:  2015-04       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.